Results of Chymopapain Chemonucleolysis
To THE EDITOR: The recent article on chemonucleolysis with chymopapain was very interesting (Shields CB, Reiss S J, Garretson HD: Chemonucleolysis with chymopapain: results in 150 patients. J Neurosurg 6 7." 187-191, August, 1987) . The authors conclude in their abstract that "these results cast doubt on the long-term benefits of chymopapain in the treatment of lumbar disc disease." Unfortunately, however, their conclusions are not supported by their own data. The authors noted a very unfavorable response rate of 40% following chymopapain chemonucleolysis in their group of patients who were contacted by means of a long-term follow-up questionnaire. They stated that the disparity between the very low success rate found in their study and the results of others (70% to 73%) cannot be due to "different methods of information retrieval alone." I agree with this comment but disagree with their analysis as to the reasons for this difference. They imply that the poor results in their series can be attributed to a failure of chymopapain to adequately treat the disc herniation. Their data indicate, however, that the real reason for a high failure rate was poor selection of patients for chemonucleolysis.
A failure of chemonucleolysis certainly cannot be implicated in the 50 patients (40%) who reported a good or excellent response. In the group of 76 patients (60%) who assessed their response as fair or poor, 53 patients at reevaluation "were not considered candidates for (postchemonucleolysis) surgery." No mention is made in the article by Dr. Shields, et al., as to why these patients were not surgical candidates. It would seem from their article that the clinical and radiographic evidence of disc disease in these patients was so minimal at reevaluation that surgical exploration was not warranted. If chemonucleolysis had failed in these 53 patients and residual disc material was present, then why were the patients not operative candidates? If no residual disc herniation was present following treatment, then either chemonucleolysis must have been effective or there was yet another unrecognized cause of the Neurosurgical forum patient's persistent pain. When considering the operative findings in the "failures" who came to surgery, I greatly suspect that the latter is true.
Among the 23 patients with persistent pain and enough evidence of disc disease to warrant surgical exploration, it is obvious that failure of chemonucleolysis can be implicated in no more than seven cases. No abnormality was found at laminectomy in five patients; central spinal or foraminal stenosis was present in 12, mechanical instability in three, scarring in one, and extruded disc fragments in three. Shields, et al., should not be surprised at the poor results of chemonucleolysis in these patients. Indeed, they are to be expected. The proper time to diagnose the above abnormalities is not after chemonucleolysis, but before. Finally, it is even unclear whether the ineffectiveness of chymopapain can be blamed for the "failure" of chemonucleolysis in the remaining seven patients. A bulging disc (redundant anulus syndrome) was found at exploration in all of these patients. From the authors' article it is not possible to determine whether the original lesion that was injected was a true disc herniation or merely a bulging redundant anulus, a condition for which chemonucleolysis is inappropriate. I also find it interesting that, in the group of 23 "failures" that came to surgery, a herniated disc was not found to be the cause of failure in any patient.
The data published by Shields, et al., do not, in fact, condemn the effectiveness of chemonucleolysis, but rather indicate the ineffectiveness of their methods of patient selection. With modern neuroradiological imaging and accurate interpretation of these studies, patients with pain syndromes that are unresponsive to chemonucleolysis (for example, foraminal stenosis, lateral recess stenosis, central spinal stenosis, hypertrophic scarring, mechanical instability, sequestered disc fragments, no abnormality, or redundant anulus syndrome) can be identified. If patients with these lesions are injected, then the blame for failure must be put where it really belongs --on a failure by physicians to properly select patients for treatment. Although it may be true that all of the injected patients in the authors' study "clearly were candidates for surgical intervention," it is equally clear that all who were injected were not candidates for chemonucleolysis. Laminectomy or conservative treatment is the only alternative in those patients who have unresponsive causes of low-back pain and sciatica.
I have attempted to view this controversial and highly charged topic with as little bias as is possible for a neuroradiologist who does not treat patients with either surgery or chemonucleolysis. As a peripheral "observer," however, I feel compelled to make several comments concerning this debate.
1. The effectiveness of chemonucleolysis cannot be judged on the basis of studies that indiscriminately treat patients with little regard to the responsiveness of the lesion to chymopapain.
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2. Many papers purporting to study the long-term effectiveness of chemonucleolysis are biased toward poor results because patients were entered into the study before the advent of water-soluble myelography and computerized tomography (CT). Accurate exclusion of untreatable causes of pain is certainly not possible with Pantopaque myelography. It is also not consistently possible with water-soluble myelography unless CT scanning is performed as well. In the early days of chymopapain therapy, many patients were treated with chemonucleolysis for "disc herniations" when in reality they had a variety of abnormalities that could not be accurately differentiated from true focal disc herniations.
3. Very rigid exclusion criteria must be used when selecting patients for chemonucleolysis to avoid injecting patients who have untreatable conditions. This is more important than when selecting patients for laminectomy. In the latter situation, the exploration can be extended if the expected disc herniation is not found at surgery.
4. Because of the importance of proper clinical selection of patients, chemonucleolysis should not be performed by neurosurgeons and orthopedic surgeons who are inexperienced in the technique. Equally important is the necessity of consulting a neuroradiologist who is experienced in spinal imaging. Critical scrutiny of the imaging studies for the presence of abnormalities responsive to treatment other than chymopapain is mandatory if good results are to be achieved. Careful collaboration of the clinician and the neuroradiologlst is essential for optimal results.
5. Chemonucleolysis should not be performed at levels associated with previous surgery unless it is possible to completely exclude scarring as the cause of the visualized extradural abnormality. Patients who have incomplete pain relief following chemonucleolysis at a previously operated level should, more properly, be considered surgery/chemonucleolysis failures.
6. Incomplete relief of pain after chemonucleolysis in patients with unresponsive lesions should not be termed a "chemonucleolysis failure" but a "selection failure."
In fairness to Shields, et al., many of their patients were selected prior to the availability of modern neuroradiological imaging (CT, magnetic resonance imaging, water-soluble myelography). Although they cannot be faulted for this limitation, they should face the real culprit of their poor results --poor patient selection. We also made many mistakes in the selection of patients for chemonucleolysis prior to the availability of CT and water-soluble myelography. ~.z It can be advantageous, however, if one learns from these mistakes rather than misplacing the blame. I believe that the study by Shields, et al., reaffirms the necessity for proper selection of patients for chymopapain chemonucleolysis. The only statement that seems valid, in their data analysis is: "with further investigation... and more rigorous exclusion of some cases, our results might be improved." LINDELL R. GENTRY, M.D.
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